Among the TLR9 agonists tested as adjuvants in vaccines against cancer cells and intracellular pathogens, CpG ODNs induce activation of both the Th1-polarized immune response, including NK cells, macrophages, and APCs, and the humoral immune response to control local tumor growth 22, 49, 50. The gene discussed is TLR9; the disease is cancer.